Logo image of BRM.CA

BIOREM INC (BRM.CA) Stock Fundamental Analysis

TSX-V:BRM - TSX Venture Exchange - CA09068G1046 - Common Stock - Currency: CAD

2.45  +0.08 (+3.38%)

Fundamental Rating

7

Taking everything into account, BRM scores 7 out of 10 in our fundamental rating. BRM was compared to 24 industry peers in the Commercial Services & Supplies industry. BRM has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. BRM scores decently on growth, while it is valued quite cheap. This could make an interesting combination. This makes BRM very considerable for value and quality investing!


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

In the past year BRM was profitable.
In the past year BRM had a positive cash flow from operations.
Each year in the past 5 years BRM has been profitable.
Each year in the past 5 years BRM had a positive operating cash flow.
BRM.CA Yearly Net Income VS EBIT VS OCF VS FCFBRM.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1M -1M 2M 3M 4M

1.2 Ratios

BRM has a better Return On Assets (12.64%) than 91.67% of its industry peers.
BRM has a better Return On Equity (30.95%) than 91.67% of its industry peers.
BRM's Return On Invested Capital of 26.24% is amongst the best of the industry. BRM outperforms 100.00% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BRM is significantly above the industry average of 7.19%.
The last Return On Invested Capital (26.24%) for BRM is above the 3 year average (25.13%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 12.64%
ROE 30.95%
ROIC 26.24%
ROA(3y)9.17%
ROA(5y)8.76%
ROE(3y)32.25%
ROE(5y)35.65%
ROIC(3y)25.13%
ROIC(5y)23.46%
BRM.CA Yearly ROA, ROE, ROICBRM.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

1.3 Margins

BRM has a Profit Margin of 7.31%. This is amongst the best in the industry. BRM outperforms 83.33% of its industry peers.
In the last couple of years the Profit Margin of BRM has grown nicely.
BRM has a Operating Margin of 10.65%. This is in the better half of the industry: BRM outperforms 79.17% of its industry peers.
BRM's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 26.49%, BRM is in line with its industry, outperforming 54.17% of the companies in the same industry.
BRM's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 10.65%
PM (TTM) 7.31%
GM 26.49%
OM growth 3Y7.19%
OM growth 5YN/A
PM growth 3Y15.35%
PM growth 5YN/A
GM growth 3Y1.79%
GM growth 5Y2.67%
BRM.CA Yearly Profit, Operating, Gross MarginsBRM.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

8

2. Health

2.1 Basic Checks

BRM has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, BRM has more shares outstanding
Compared to 5 years ago, BRM has less shares outstanding
BRM has a better debt/assets ratio than last year.
BRM.CA Yearly Shares OutstandingBRM.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
BRM.CA Yearly Total Debt VS Total AssetsBRM.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

An Altman-Z score of 4.55 indicates that BRM is not in any danger for bankruptcy at the moment.
The Altman-Z score of BRM (4.55) is better than 95.83% of its industry peers.
The Debt to FCF ratio of BRM is 0.91, which is an excellent value as it means it would take BRM, only 0.91 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.91, BRM belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
A Debt/Equity ratio of 0.30 indicates that BRM is not too dependend on debt financing.
With an excellent Debt to Equity ratio value of 0.30, BRM belongs to the best of the industry, outperforming 83.33% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF 0.91
Altman-Z 4.55
ROIC/WACC3.5
WACC7.5%
BRM.CA Yearly LT Debt VS Equity VS FCFBRM.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M

2.3 Liquidity

BRM has a Current Ratio of 1.91. This is a normal value and indicates that BRM is financially healthy and should not expect problems in meeting its short term obligations.
BRM has a better Current ratio (1.91) than 87.50% of its industry peers.
BRM has a Quick Ratio of 1.66. This is a normal value and indicates that BRM is financially healthy and should not expect problems in meeting its short term obligations.
With a decent Quick ratio value of 1.66, BRM is doing good in the industry, outperforming 79.17% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.91
Quick Ratio 1.66
BRM.CA Yearly Current Assets VS Current LiabilitesBRM.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

6

3. Growth

3.1 Past

BRM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -13.75%.
BRM shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 32.08% yearly.
The Revenue has grown by 51.00% in the past year. This is a very strong growth!
The Revenue has been growing by 12.63% on average over the past years. This is quite good.
EPS 1Y (TTM)-13.75%
EPS 3Y32.08%
EPS 5YN/A
EPS Q2Q%-89.13%
Revenue 1Y (TTM)51%
Revenue growth 3Y15.2%
Revenue growth 5Y12.63%
Sales Q2Q%-20.07%

3.2 Future

Based on estimates for the next years, BRM will show a very strong growth in Earnings Per Share. The EPS will grow by 23.54% on average per year.
BRM is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.45% yearly.
EPS Next Y15.79%
EPS Next 2Y23.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year7.05%
Revenue Next 2Y8.45%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
BRM.CA Yearly Revenue VS EstimatesBRM.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M 40M
BRM.CA Yearly EPS VS EstimatesBRM.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 0.05 0.1 0.15 0.2 0.25

8

4. Valuation

4.1 Price/Earnings Ratio

BRM is valuated correctly with a Price/Earnings ratio of 14.41.
Based on the Price/Earnings ratio, BRM is valued cheaply inside the industry as 87.50% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 27.51. BRM is valued slightly cheaper when compared to this.
With a Price/Forward Earnings ratio of 8.20, the valuation of BRM can be described as very reasonable.
87.50% of the companies in the same industry are more expensive than BRM, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 35.58. BRM is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 14.41
Fwd PE 8.2
BRM.CA Price Earnings VS Forward Price EarningsBRM.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BRM indicates a rather cheap valuation: BRM is cheaper than 87.50% of the companies listed in the same industry.
BRM's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BRM is cheaper than 91.67% of the companies in the same industry.
Industry RankSector Rank
P/FCF 9.63
EV/EBITDA 7.16
BRM.CA Per share dataBRM.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

BRM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of BRM may justify a higher PE ratio.
BRM's earnings are expected to grow with 23.54% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.91
PEG (5Y)N/A
EPS Next 2Y23.54%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for BRM!.
Industry RankSector Rank
Dividend Yield N/A

BIOREM INC

TSX-V:BRM (7/14/2025, 7:00:00 PM)

2.45

+0.08 (+3.38%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCommercial & Professional Services
GICS IndustryCommercial Services & Supplies
Earnings (Last)05-15 2025-05-15
Earnings (Next)08-25 2025-08-25
Inst Owners0.16%
Inst Owner ChangeN/A
Ins Owners1.98%
Ins Owner ChangeN/A
Market Cap39.49M
Analysts84.44
Price Target4.08 (66.53%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-11.11%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.99%
Valuation
Industry RankSector Rank
PE 14.41
Fwd PE 8.2
P/S 0.94
P/FCF 9.63
P/OCF 9.4
P/B 3.97
P/tB 3.97
EV/EBITDA 7.16
EPS(TTM)0.17
EY6.94%
EPS(NY)0.3
Fwd EY12.19%
FCF(TTM)0.25
FCFY10.39%
OCF(TTM)0.26
OCFY10.64%
SpS2.61
BVpS0.62
TBVpS0.62
PEG (NY)0.91
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 12.64%
ROE 30.95%
ROCE 34.64%
ROIC 26.24%
ROICexc 59.83%
ROICexgc 59.83%
OM 10.65%
PM (TTM) 7.31%
GM 26.49%
FCFM 9.73%
ROA(3y)9.17%
ROA(5y)8.76%
ROE(3y)32.25%
ROE(5y)35.65%
ROIC(3y)25.13%
ROIC(5y)23.46%
ROICexc(3y)41.23%
ROICexc(5y)N/A
ROICexgc(3y)41.23%
ROICexgc(5y)N/A
ROCE(3y)33.17%
ROCE(5y)30.97%
ROICexcg growth 3Y-30.69%
ROICexcg growth 5YN/A
ROICexc growth 3Y-30.69%
ROICexc growth 5YN/A
OM growth 3Y7.19%
OM growth 5YN/A
PM growth 3Y15.35%
PM growth 5YN/A
GM growth 3Y1.79%
GM growth 5Y2.67%
F-Score6
Asset Turnover1.73
Health
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF 0.91
Debt/EBITDA 0.6
Cap/Depr 18.68%
Cap/Sales 0.24%
Interest Coverage 250
Cash Conversion 83.68%
Profit Quality 133.16%
Current Ratio 1.91
Quick Ratio 1.66
Altman-Z 4.55
F-Score6
WACC7.5%
ROIC/WACC3.5
Cap/Depr(3y)93.69%
Cap/Depr(5y)79.96%
Cap/Sales(3y)1.3%
Cap/Sales(5y)1.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-13.75%
EPS 3Y32.08%
EPS 5YN/A
EPS Q2Q%-89.13%
EPS Next Y15.79%
EPS Next 2Y23.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)51%
Revenue growth 3Y15.2%
Revenue growth 5Y12.63%
Sales Q2Q%-20.07%
Revenue Next Year7.05%
Revenue Next 2Y8.45%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.31%
EBIT growth 3Y23.48%
EBIT growth 5YN/A
EBIT Next Year38.31%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y51.49%
FCF growth 3Y-3.66%
FCF growth 5Y6.73%
OCF growth 1Y41.83%
OCF growth 3Y-0.86%
OCF growth 5Y7.83%